No annual revenue total was found in Rapport Therapeutics, Inc.'s SEC filings.
Rapport Therapeutics, Inc. (RAPP) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$88.1 million. As of Sep 30, 2026 it held $395.0 million in cash and investments and $9.4 million in total debt.
Revenue
—
Net income (TTM)
$-150.47M
-54.0% vs year-ago TTM
Operating cash flow (TTM)
$-120.85M
-56.5% vs year-ago TTM
Free cash flow (TTM)
$-121.18M
-55.6% vs year-ago TTM
EPS (TTM)
$-3.18
-16.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
47.79M
+31.0% vs prior year
Net cash
$385.64M
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RAPP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 2012593
- Former names
- Rapport Therapeutics, Inc. (until Nov 4, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Operating income | -$125.1M | -$83.1M |
| Net income | -$111.5M | -$78.3M |
| Diluted EPS | -$2.86 | -$3.78 |
| Operating cash flow | -$87.5M | -$64.8M |
| Free cash flow | -$88.1M | -$67.2M |
| Total assets | $512.4M | $314.9M |
| Total liabilities | $27.8M | $9.5M |
| Stockholders' equity | $484.7M | $305.4M |
| Cash and investments | $490.5M | $305.3M |
| Total debt | $11.5M | $1.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Material agreement, Results of operations, New debt, Unregistered share sale
|
Oct 30, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 20, 2026 | Oct 20, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
All 253 Rapport Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.